Daiichi Sankyo & Merck voluntarily withdraws patritumab deruxtecan BLA to treat locally advanced or metastatic EGFR-mutated NSCLC from US FDA: Basking Ridge, New Jersey Friday, Ma ...

The firm submitted data showing that more than 70 percent of patients with HER2-mutated NSCLC who hadn't received anti-HER2 therapy responded to sevabertinib.

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...

Merck & Co Inc. (MRK) and Daiichi Sankyo on Thursday said that the companies have withdrawn their application to the U.S.

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

Merck and Daiichi Sankyo, which were seeking approval of patritumab deruxtecan for adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer previously treated with two or ...

Merck (MRK) stock falls as the company withdraws U.S. marketing application for lung cancer therapy HER3-DXd developed with ...